Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and ...

The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will also be archived for a minimum of thirty days.

SPRING HOUSE, PA – Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S ...

If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as ...

Johnson & Johnson (NYSE: JNJ) shares gained ground Friday, as the company announced the submission of a supplemental ...

The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...

Johnson & Johnson announced the submission of a supplemental Biologics License Application to the U.S. FDA seeking approval of a ...

Johnson & Johnson (JNJ) announced the submission of a supplemental Biologics License Application to the FDA seeking approval of a ...

US healthcare giant Johnson & Johnson has filed a supplemental Biologics License Application with the US Food and Drug ...

J&J JNJ stock has plunged 6.1% in a month, losing almost $24 billion of its market value. Though slowing sales in its MedTech ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...